Advertisement

Current Urology Reports

, 19:63 | Cite as

Novel Therapy for Male Hypogonadism

  • Robert Carrasquillo
  • Kevin Chu
  • Ranjith Ramasamy
Andrology and Infertility (L Lipshultz, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Andrology and Infertility

Abstract

Purpose of Review

Hypogonadism and the treatment of low testosterone is increasingly a subject of medical inquiry and controversy. The few treatments that are FDA-approved such as testosterone topicals, injections, and pellets create significant demand from patients for treatments with more convenient means of administration, fewer adverse effects, and the ability to maintain male fertility. Off-label drugs are in abundant use for low testosterone, including selective estrogen receptor modulators, gonadotropins, and aromatase inhibitors.

Recent Findings

In this review, we summarize the evidence in support of commonly used treatments for male hypogonadism, as well as discuss recent updates in the development of novel therapeutics.

Summary

New therapies include nasal testosterone, new oral testosterone formulations, anabolic-androgenic steroids, and selective androgen receptor modulators.

Keywords

Hypogonadism Testosterone Testosterone replacement therapy SARM Clomiphene 

Notes

Compliance with Ethical Standards

Conflict of Interest

Robert Carrasquillo and Kevin Chu each declare no potential conflicts of interest.

Ranjith Ramasamy is the lead investigator on clinical trials for use of Natesto in treatment of hypogonadism with Aytu BioScience (ClinicalTrials.gov Identifier NCT03203681).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:• Of importance

  1. 1.
    Sigalos JT, Pastuszak AW, Khera M. Hypogonadism: therapeutic risks, benefits, and outcomes. Med Clin N Am. 2018;102(2):361–72.CrossRefPubMedGoogle Scholar
  2. 2.
    Surampudi PN, Wang C, Swerdloff R. Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int J Endocrinol. 2012;2012:1–20.CrossRefGoogle Scholar
  3. 3.
    Vermeulen A. Physiology of the testosterone-binding globulin in man. Ann N Y Acad Sci. 1988;538:103–11.CrossRefPubMedGoogle Scholar
  4. 4.
    Huhtaniemi I. Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment. Asian J Androl. 2014;16(2):192–202.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Wu FCW, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35.CrossRefPubMedGoogle Scholar
  6. 6.
    Araujo AB, O’Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study. J Clin Endocrinol Metab. 2004;89(12):5920–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73(5):1016–25.CrossRefPubMedGoogle Scholar
  8. 8.
    Araujo AB, Esche GR, Kupelian V, O’Donnell AB, Travison TG, Williams RE, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update. 2000;6(3):212–24.CrossRefPubMedGoogle Scholar
  10. 10.
    Mroueh A, Lytton B, Kase N. Effect of clomiphene citrate on oligospermia. Am J Obstet Gynecol. 1967;98(8):1033–6.CrossRefPubMedGoogle Scholar
  11. 11.
    • DiGiorgio L, Sadeghi-Nejad H. Off label therapies for testosterone replacement. Transl Androl Urol. 2016;5(6):844–9. This study summarizes key off-label treatments for hypogonadism, highlighting the importance of treatments that preserve fertility such as SERMs. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Surampudi P, Swerdloff RS, Wang C. An update on male hypogonadism therapy. Expert Opin Pharmacother. 2014;15(9):1247–64.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Rodriguez KM, Pastuszak AW, Lipshultz LI. Enclomiphene citrate for the treatment of secondary male hypogonadism. Expert Opin Pharmacother. 2016;17(11):1561–7.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Katz DJ, Nabulsi O, Tal R, Mulhall JP. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int. 2012;110(4):573–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Seminara SB, Hayes FJ, Crowley WF. Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann’s syndrome): pathophysiological and genetic considerations. Endocr Rev. 1998;19(5):521–39.PubMedGoogle Scholar
  16. 16.
    Happ J, Ditscheid W, Krause U. Pulsatile gonadotropin-releasing hormone therapy in male patients with Kallmann’s syndrome or constitutional delay of puberty. Fertil Steril. 1985;43(4):599–608.CrossRefPubMedGoogle Scholar
  17. 17.
    Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley WF. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2002;87(9):4128–36.CrossRefPubMedGoogle Scholar
  18. 18.
    • Vignera SL, Condorelli RA, Cimino L, Russo GI, Morgia G, Calogero AE. Late-onset hypogonadism: the advantages of treatment with human chorionic gonadotropin rather than testosterone. Aging Male. 2015;19(1):34–9. This study brings to light the use of hCG as an alternative to testosterone therapy. It may allow for the alleviation of symptoms by maintaining more physiologic levels of endogenous testosterone with fewer side effects. CrossRefPubMedGoogle Scholar
  19. 19.
    Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol. 2002;167(2 Pt 1):624–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Pavlovich CP, King P, Goldstein M, Schlegel PN. Evidence of a treatable endocrinopathy in infertile men. J Urol. 2001;165(3):837–41.CrossRefPubMedGoogle Scholar
  21. 21.
    Saylam B, Efesoy O, Cayan S. The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril. 2011;95(2):809–11.CrossRefPubMedGoogle Scholar
  22. 22.
    Gregoriou O, Bakas P, Grigoriadis C, Creatsa M, Hassiakos D, Creatsas G. Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios. Fertil Steril. 2012;98(1):48–51.CrossRefPubMedGoogle Scholar
  23. 23.
    Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011–22.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Edelstein D, Sivanandy M, Shahani S, Basari S. The latest options and future agents for treating male hypogonadism. Expert Opin Pharmacother. 2007;8(17):2991–3008.CrossRefPubMedGoogle Scholar
  25. 25.
    Wynia B, Kamintsky JC. Current and emerging testosterone therapies for male hypogonadism. Res Rep Endocr Disord. 2015;5:59–69.Google Scholar
  26. 26.
    Ceponis J, Yadav P, Swerdloff RS, Wang C. Chapter 11: Testosterone therapy: transdermal androgens. Testosterone: from basic to clinical aspects. Springer, 2017.Google Scholar
  27. 27.
    Hackett G, Kirby M, Edwards D, Jones TH, Wylie K, Ossi-Gerning N, David J, Muneer, A. British society for sexual medicine guide-lines on adult testosterone deficiency, with statements for UK practice. J Sex Med. 2017;14(12):1504–23.Google Scholar
  28. 28.
    Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: history, development, and pharmacology. Br J Pharmacol. 2015;172(9):2179–209.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    ANDRODERM (testosterone patch) [prescribing information]. Watson Pharma, Inc. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020489s025lbl.pdf. Accessed 13 March 2018.
  30. 30.
    Hadgraft J, Lane ME. Transdermal delivery of testosterone. Eur J Pharm Biopharm. 2015;92:42–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Ullah MI, Riche DM, Koch CA. Transdermal testosterone replacement therapy in men. Drug Des Devel Ther. 2014;8:101–12.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in Hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2839–53.PubMedGoogle Scholar
  33. 33.
    Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol. 2016;5(6):834–43.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Behre HM, Abshagen K, Oettel M, Hubler D, Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol. 1999;140:414–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Pfeil E, Dobs AS. Current and future testosterone delivery systems for treatment of the hypogonadal male. Expert Opin Drug Deliv. 2009;5(4):471–81.CrossRefGoogle Scholar
  36. 36.
    Testopel (testosterone pellets). prescribing information. Rye: Slate pharmaceuticals, Inc.; 2013.Google Scholar
  37. 37.
    McCullough AR, Khera M, Goldstein I, Hellstrom WJG, Morgentaler A, Levine LA. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel) insertion. J Sex Med. 2012;9(2):594–601.CrossRefPubMedGoogle Scholar
  38. 38.
    Banks WA, Morley JE, Niehoff ML, Mattern C. Delivery of testosterone to the brain by intranasal administration: comparison to intravenous testosterone. J Drug Target. 2009;17(2):91–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Mattern C, Hoffmann C, Morley JE, Badiu C. Testosterone supplementation for hypogonadal men by the nasal route. Aging Male. 2008;11(4):171–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Rogol AD, Tkachenko N, Bryson N. Natesto™, a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men. Andrology. 2016;4(1):46–54.CrossRefPubMedGoogle Scholar
  41. 41.
    • Conners W, Morgentaler A, Guidry M, Westfield G, Bryson N, Goldstein I. Proceedings of the American Urological Association Annual Meeting. J Urol. 2017;197 Supp 4S; Poster MP89–06. Online at: http://www.jurology.com/article/S0022-5347(17)61534270-2/pdf. Accessed 13 March 2018. This study represents preliminary findings suggestive that nasal testosterone may allow for treatment of hypogonadism with fertility preservation. Confirmatory clinical trials are now underway.
  42. 42.
    Wang C, Swerdloff R, Kipnes M, Matsumoto AM, Dobs AS, Cunningham G, et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab. 2004;89(8):3821–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Boyer JL, Preisig R, Zbinden G, de Kretser DM, Wang C, Paulsen CA. Guidelines for assessment of potential hepatotoxic effects of synthetic androgens, anabolic agents and progestagens in their use in males as antifertility agents. Contraception. 1976;13(4):461–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–59.CrossRefPubMedGoogle Scholar
  45. 45.
    Friedl KE, Hannan CJ, Jones RE, Plymate SR. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism. 1990;39(1):69–74.CrossRefPubMedGoogle Scholar
  46. 46.
    Horst HJ, Höltje WJ, Dennis M, Coert A, Geelen J, Voigt KD. Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klin Wochenschr. 1976;54(18):875–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Nieschlag E, Mauss J, Coert A, Kićović P. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol. 1975;79(2):366–74.PubMedGoogle Scholar
  48. 48.
    Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol. 1981;14(1):49–61.CrossRefGoogle Scholar
  49. 49.
    Yin AY, Htun M, Swerdloff RS, Diaz-Arjonilla M, Dudley RE, Faulkner S, et al. Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation. J Androl. 2012;33(2):190–201.CrossRefPubMedGoogle Scholar
  50. 50.
    Ault A. FDA panel votes down oral testosterone replacement products. Medscape News. 2018. Accessed: 2018 Feb 24. Online at: https://www.medscape.com/viewarticle/891186?src=rss#vp_1.
  51. 51.
    US Drug Enforcement Agency. Designer anabolic steroid control act of 2014. https://www.cbo.gov/publication/45595. Accessed 13 March 2018.
  52. 52.
    Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271–9.CrossRefPubMedGoogle Scholar
  53. 53.
    • Wu C, Kovac JR. Novel uses for the anabolic androgenic steroids nandrolone and oxandrolone in the management of male health. Curr Urol Rep. 2016;17(10):72. This review summarizes data regarding anabolic steroids that suggests they may be of benefit in hypogonadal men from their more potent myotrophic qualities. CrossRefPubMedGoogle Scholar
  54. 54.
    Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502–21.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Mulligan K, Schambelan M. Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting. Int J Cardiol. 2002;85(1):151–9.CrossRefPubMedGoogle Scholar
  56. 56.
    Sharma S, Arneja A, McLean L, Duerksen D, Leslie W, Sciberras D, et al. Anabolic steroids in COPD: a review and preliminary results of a randomized trial. Chron Respir Dis. 2008;5(3):169–76.CrossRefPubMedGoogle Scholar
  57. 57.
    Chen CT, Lin SH, Chen JS, Hsu YJ. Muscle wasting in hemodialysis patients: new therapeutic strategies for resolving an old problem. ScientificWorldJournal. 2013;2013:643954.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Vogel RB, Books CA, Ketchum C, Zauner CW, Murray FT. Increase of free and total testosterone during submaximal exercise in normal males. Med Sci Sports Exerc. 1985;17(1):119–23.CrossRefPubMedGoogle Scholar
  59. 59.
    Häkkinen K, Pakarinen A, Kraemer WJ, Newton RU, Alen M. Basal concentrations and acute responses of serum hormones and strength development during heavy resistance training in middle-aged and elderly men and women. J Gerontol A Biol Sci Med Sci. 2000;55(2):B95–105.CrossRefPubMedGoogle Scholar
  60. 60.
    Häkkinen K, Kraemer WJ, Pakarinen A, Triplett-McBride T, McBride JM, Häkkinen A, et al. Effects of heavy resistance/power training on maximal strength, muscle morphology, and hormonal response patterns in 60-75-year-old men and women. Can J Appl Physiol. 2002;27(3):213–31.CrossRefPubMedGoogle Scholar
  61. 61.
    Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs. 2004;64(7):725–50.CrossRefPubMedGoogle Scholar
  62. 62.
    Rosenfeld J, King RM, Smith JE. Oxandrolone in ALS: preliminary analysis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(Suppl 4):21–5. discussion 5-6CrossRefPubMedGoogle Scholar
  63. 63.
    Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R. Oxandrolone in AIDS-wasting myopathy. AIDS. 1996;10(14):1657–62.CrossRefPubMedGoogle Scholar
  64. 64.
    Fenichel GM, Griggs RC, Kissel J, Kramer TI, Mendell JR, Moxley RT, et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology. 2001;56(8):1075–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Yeh SS, DeGuzman B, Kramer T, Group MS. Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest. 2002;122(2):421–8.CrossRefPubMedGoogle Scholar
  66. 66.
    Choi SM, Lee BM. Comparative safety evaluation of selective androgen receptor modulators and anabolic androgenic steroids. Expert Opin Drug Saf. 2015;14(11):1773–85.CrossRefPubMedGoogle Scholar
  67. 67.
    Cozzoli A, Capogrosso RF, Sblendorio VT, Dinardo MM, Jagerschmidt C, Namour F, et al. GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy. Pharmacol Res. 2013;72:9–24.CrossRefPubMedGoogle Scholar
  68. 68.
    Zhang X, Sui Z. Deciphering the selective androgen receptor modulators paradigm. Expert Opin Drug Discov. 2013;8(2):191–218.CrossRefPubMedGoogle Scholar
  69. 69.
    Yi P, Rehmel JF, Cassidy K, Hadden C, Campanale K, Patel N, et al. Disposition and metabolism of LY2452473, a selective androgen receptor modulator, in humans. Drug Metab Dispos. 2012;40(12):2354–64.CrossRefPubMedGoogle Scholar
  70. 70.
    Dalton JT, Taylor RP, Mohler ML, Steiner MS. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr Opin Support Palliat Care. 2013;7(4):345–51.CrossRefPubMedGoogle Scholar
  71. 71.
    Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677–85.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Robert Carrasquillo
    • 1
  • Kevin Chu
    • 1
  • Ranjith Ramasamy
    • 1
  1. 1.Department of UrologyUniversity of Miami Miller School of MedicineMiamiUSA

Personalised recommendations